Regulation - Insmed

Filter

Current filters:

Insmed

Popular Filters

The case for Insmed's CF drug candidate Arikace; analysts' views

05-07-2013

The 16% decline in US biotech firm Insmed's (Nasdaq CM: INSM) stock is an overreaction to results from…

ArikaceBiotechnologyFinancialInsmedRare diseasesRegulationResearchRespiratory and Pulmonary

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top